Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 31Other solid neoplasm 26Thoracic 13Myeloid 12Gastrointestinal 10Breast 7Plasma cell 4Lymphoid 4Gynecologic 4Head & Neck 3Genitourinary 3CNS 3Classical hematology 2Tumor-Agnostic 1Sarcoma 1NET 1Endocrine 1

Conditions

Gastroenteropancreatic Neuroendocrine Tumors 1

Interventions

Magnetic Resonance Spectroscopy 15lutetium Lu 177 dotatate 14Specimen Handling 14cabozantinib 10Nivolumab 10Everolimus 8pembrolizumab 7gallium Ga 68 dotatate 6Ipilimumab 6Cisplatin 5Carboplatin 5trametinib 4olaparib 4lenvatinib 4X-Rays 4Lutetium-177 4Etoposide 4Cyclophosphamide 4CTLA-4 Antigen 4fluorodopa F 18 3fludarabine 3dabrafenib 3cemiplimab 3Temozolomide 3Phantoms, Imaging 3Fluorodeoxyglucose F18 3Blood Specimen Collection 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3selpercatinib 2lanreotide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Injections × Endocrine × 90 days × Clear all
NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡